Ottobock SE & Co. KGaA
12.55
USD
-2.65
(-17.43%)
CIK
2094691
ISIN
US68968P1012
CUSIP
68968P101
Return %
Stock
S&P 500
1Y
- -
14.20
3Y
- -
81.12
5Y
- -
68.34
Capital Structure
EUR
•
in mil. unless spec.Working Capital
EUR
•
in mil. unless spec.Growth Rates
EUR
•
in mil. unless spec.Quarterly Revenue
EUR
•
in mil. unless spec.Quarterly Earnings Per Share
EUR
•
in mil. unless spec.Quarterly Dividends Per Share
EUR
•
in mil. unless spec.Company Description
- CEO
- Oliver Jakobi
- Full Time Employees
- 10,365
- Sector
- Health technology
- Industry
- Medical specialties
- Address
- Duderstadt Germany
- Website
- ottobock.com
- Similar Companies
- Business
- Ottobock SE & Co. KGaA is a global medical technology and human bionics company that specializes in the development, manufacturing, and fitting of advanced prosthetics, orthotics, neuro-orthotics, and industrial exoskeletons. Founded in 1919 and headquartered in Duderstadt, Germany, the company operates under parent entity Näder Holding SE & Co. KGaA and delivers mobility solutions across more than 45 countries worldwide. Ottobock organizes its business across core operational segments, including Prosthetics, Neuro-Orthotics, Bionic Exoskeletons, and Patient Care. The company's comprehensive product and service portfolio includes lower-limb prosthetic solutions such as the microprocessor-controlled C-Leg, Genium, Genium X3, and Kenevo knee joints, alongside dynamic prosthetic feet like the Taleo and Triton product lines; upper-limb bionic prostheses comprising the Michelangelo hand, bebionic multi-articulating hand, and Myo Facil systems; neuro-orthotic and orthotic devices, including the microprocessor-controlled C-Brace orthotronic mobility system, Agilium osteoarthritis knee braces, Dorso Arexa spinal supports, and Functional Electrical Stimulation (FES) systems for neurological rehabilitation; industrial ergonomic exoskeletons developed under the Ottobock Bionic Exoskeletons line, including the Ottobock Shoulder (formerly Paexo Shoulder), Ottobock Back, and SuitX wearable systems designed to reduce musculoskeletal strain in manufacturing and logistics environments; and Patient Care services delivered through a global network of over 430 specialized orthopaedic clinics that provide custom fitting, clinical assessment, digital fabrication, and rehabilitation therapy for patients with mobility impairments. In recent strategic developments, Ottobock has accelerated its transformation into a dedicated bionics and neuro-orthotics leader. In 2026, the company entered into an agreement to divest its Human Mobility wheelchair business to DHCare in order to concentrate capital and research on its core bionic technology portfolio. Ottobock also expanded its neuro-rehabilitation capabilities through the acquisition of Spanish medical device company Fesia Technology in 2026, integrating advanced surface electrical stimulation solutions into its neuro-orthotics offering. To bolster its direct clinical footprint, the company acquired the Norwegian patient care operations of Blatchford Ltd. in 2026 and Danish orthopaedic provider Sahva A/S in 2024. On the corporate structure front, the founding Näder family completed the buyback of a 20% minority stake from private equity firm EQT in March 2024, restoring 100% family ownership supported by private debt financing. Furthermore, the company continues to advance product innovation, recently introducing AI-powered myosmart plus control for the Michelangelo hand, the C-Brace Interim system for early-phase paralysis rehabilitation, and Iconiq 3D-printed silicone liners.